Literature DB >> 15225884

Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review.

Michael McDonough1, Noel Kennedy, Anthony Glasper, Jenny Bearn.   

Abstract

AIM: To examine the clinical course of gamma-hydroxybutyrate (GHB) withdrawal and generate management guidelines.
DESIGN: Review and analysis of all published reports of GHB or GHB precursor withdrawal identified from electronic searches.
FINDINGS: In total, 38 cases of GHB (n = 28) or GHB precursor (n = 10) withdrawal were identified, 36 of which were from the US. A rapidly deteriorating course into delirium (53% of cases) was typical for heavily dependent users. Symptoms were broadly similar to alcohol withdrawal but often occurred earlier in usage with delirium being associated with severe dependence as determined by more frequent ingestion. High dose benzodiazepines were effective in pharmacological management of GHB withdrawal. In benzodiazepine refractory cases withdrawal responded to other sedative agents, mainly pentobarbital or chloral hydrate. No withdrawal seizures but one death was recorded.
CONCLUSIONS: GHB withdrawal is potentially life threatening and requires vigorous clinical management, preferably as an inpatient for severe cases. A management algorithm is proposed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15225884     DOI: 10.1016/j.drugalcdep.2004.01.012

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  20 in total

1.  Gamma-hydroxybutyrate withdrawal syndrome: a case report.

Authors:  Michael A Kuiper; Nicole Peikert; E Christiaan Boerma
Journal:  Cases J       Date:  2009-03-25

2.  Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.

Authors:  Amy K Goodwin; Roland R Griffiths; P Rand Brown; Wolfgang Froestl; Cornelis Jakobs; K Michael Gibson; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2006-09-20       Impact factor: 4.530

Review 3.  Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.

Authors:  Rama M Kamal; Martijn S van Noorden; Wim Wannet; Harmen Beurmanjer; Boukje A G Dijkstra; Arnt Schellekens
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

4.  Psychosis in the context of sodium oxybate therapy.

Authors:  Jody Langford; William L Gross
Journal:  J Clin Sleep Med       Date:  2011-12-15       Impact factor: 4.062

5.  Physical dependence on gamma-hydroxybutrate (GHB) prodrug 1,4-butanediol (1,4-BD): time course and severity of withdrawal in baboons.

Authors:  Amy K Goodwin; K Michael Gibson; Elise M Weerts
Journal:  Drug Alcohol Depend       Date:  2013-03-26       Impact factor: 4.492

Review 6.  Behavioral analyses of GHB: receptor mechanisms.

Authors:  Lawrence P Carter; Wouter Koek; Charles P France
Journal:  Pharmacol Ther       Date:  2008-10-29       Impact factor: 12.310

7.  Self-administration of gamma-hydroxybutyric acid (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons.

Authors:  Amy K Goodwin; Barbara J Kaminski; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2012-09-04       Impact factor: 4.530

Review 8.  Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence.

Authors:  Gillian M Keating
Journal:  Clin Drug Investig       Date:  2014-01       Impact factor: 2.859

9.  Baclofen and gamma-hydroxybutyrate withdrawal.

Authors:  Jennifer L LeTourneau; Daniel S Hagg; Stephen M Smith
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

10.  Chronic gamma-hydroxybutyric-acid use followed by gamma-hydroxybutyric-acid withdrawal mimic schizophrenia: a case report.

Authors:  Prometheas Constantinides; Philippe Vincent
Journal:  Cases J       Date:  2009-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.